Enrofloxacin

Category	Orthopoxvirus
CAS	93106-60-6
Description	Enrofloxacin is a fluoroquinolone antibiotic that prevents DNA superhelix and DNA synthesis by inhibiting bacterial DNA gyrase (a type II topoisomerase). It can be used for bacterial diseases caused by sensitive bacteria in livestock and small animals.

Quotation Now

Product Information

Synonyms	Baytril; Enrofloxacine; CFPQ; Enrofloxacino; Bay Vp 2674
IUPAC Name	1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid
Molecular Weight	359.39
Molecular Formula	C19H22FN3O3
Canonical SMILES	CCN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)F
InChI	InChI=1S/C19H22FN3O3/c1-2-21-5-7-22(8-6-21)17-10-16-13(9-15(17)20)18(24)14(19(25)26)11-23(16)12-3-4-12/h9-12H,2-8H2,1H3,(H,25,26)
InChIKey	SPFYMRJSYKOXGV-UHFFFAOYSA-N
Boiling Point	560.5±50.0°C (Predicted)
Melting Point	219-221°C
Flash Point	292.8±30.1 °C
Purity	>98%
Density	1.385±0.06 g/cm3 (Predicted)
Solubility	Slightly soluble in Chloroform, Methanol (Very Heated)
Appearance	Pale Yellow to Pale Beige Solid
Storage	Store at -20°C
Animal Admin	11- to 14-week-old C57Bl6/J male mice are used. Enrofloxacin (2.5% oral solution) is dispensed in saline (2 mg/mL), antibiotic-treated animals receive a daily orally dispensed dose of 10 mg/kg body weight via feeding needle every 12 hours over a period of 7 days, while placebo animals receive the same amount of saline via feeding needle. Animals of preventive antibiotic group obtained Enrofloxacin after waking from reperfusion anesthesia (ca. 1 hour after operation). Therapeutic antibiotic treatment is given immediately after appearance of clinical signs (general health score>5) and confirmation of lung infection by MRI (signal rate≥5%). The group allocation is randomized.
Complexity	613
Exact Mass	359.16451973
Index Of Refraction	1.634
In Vitro	Mycoplasma bovis is a worldwide pathogen, causative agent of pneumonia, mastitis, arthritis, and a variety of other symptoms in cattle. The antibiotic susceptibility profiles of the Hungarian strains are consistent within the tested group of fluoroquinolones. Three isolates (MYC44, MYC45 and MYC46) have high MIC values (≥10 μg/mL) to Enrofloxacin, while the rest of the strains are inhibited by Enrofloxacin with MICs ≤ 0.312 or 0.625 μg/mL.
In Vivo	Mice (n=80) undergo transient middle cerebral artery occlusion (MCAo) with reperfusion after 60 minutes. After MCAo, animals are randomly assigned to receive either a daily preventive medication (n=26, Enrofloxacin) starting at the day of MCAo or a therapeutic medication (n=25; Enrofloxacin) after diagnosis of lung infection. Standard treatment started immediately after the appearance of clinical signs (general health score>6) usually between day 4 and 6 after stroke. Both, preventive and standard antibiotic treatment using Enrofloxacin improve survival in a similar way compared with placebo treatment.
PSA	65.78000
Target	MIC90: 0.312 μg/mL ( Mycoplasma bovis)
Vapor Pressure	0.0±1.6 mmHg at 25°C
XLogP3-AA	-0.2